Cytokine gene transduction into non-immunogeneic murine tumor cells

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 2, 1998, Pages 87-94

  Morecki, Shoshana ^a   Lubina Salomon, Alexandra ^a   Slavin, Shimon ^a   Nagler, Arnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cytokine; Gene transfer; Immunogenicity; Tumorigenicity

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PROTEIN BCL 2; RECOMBINANT GAMMA INTERFERON;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; BREAST CARCINOMA; CANCER SURVIVAL; CARCINOGENICITY; CONTROLLED STUDY; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; TUMOR CELL;

ANIMALS; CELL TRANSPLANTATION; CYTOKINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERFERON-GAMMA, RECOMBINANT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0031821738     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Rosenberg SA, Immunotherapy and gene therapy of cancer. Cancer Res (1991) 51: 5074s-9s.
2. Blankenstein T, Rowley DA, Schreiber H, Cytokines and cancer: experimental systems. Curr Opin Immunol (1991) 3: 694-8.
3. Foa R, Guarini A, Cignetti A et al, Cytokine gene therapy: a new strategy for the management of cancer patients. Nat Immun (1994) 13: 65-75.
4. Tepper RI, Mule JJ, Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther (1994) 5: 153-64.
5. Pardoll DM, Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol (1995) 13: 399-415
6. Forni G, Cavallo F, Consalvo M et al, Molecular approaches to cancer immunotherapy. Cytokines Mol Ther (1995) 1: 225-48.
7. Forni G, Giovarelli M, Cavallo F et al, Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. J Immunother (1993) 14: 253-7.
8. Miller AR, McBride WH, Hunt K, Economou JS, Cytokine-mediated gene therapy for cancer. Ann Surg Oncol (1994) 1: 436-50.
9. Hock H, Dorsch M, Richter G et al, Tumor-cell-targeted cytokine gene transfer in experimental models for cancer therapy. Nat Immun (1994) 13. 85-92.
10. Dranoff G, Jaffee E, Lazenby A et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90: 3539-3543.
11. Dexter DL, Kowalski HM, Blazar BA et al, Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res (1978) 38: 3174-81.
12. Resnitzky P, Estrov Z, Haran-Ghera N, High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids. Leuk Res (1985) 9: 1519-28.
13. Slavin S, Strober S, Spontaneous murine B-cell leukemia. Nature (1978) 272: 624-6.
14. Danos O, Mulligan RC, Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA (1988) 85: 6460-4.
15. Gillis S, Ferm MM, Ou W, Smith KA, T cell growth factor-parameters of production and a quantitative microassay for activity. J Immunol (1978) 120: 2027-32.
16. Morecki S, Moshel Y, Gelfend Y et al, Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer (1997) 71: 59-63.
17. Fearon E, Pardoll DM, Itaya E et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60: 397-403.
18. Esumi N, Hunt B, Itaya T, Frost P, Reduced tumorigenicity of tumor cells secreting γ interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res (1991) 51: 1185-9
19. Porgador A, Feldman M, Eisenbach L, Immunotherapy of tumor metastasis via gene therapy. Nat Immun (1994) 13: 113-30.
20. Operator A, Gansbacher B, Bannerji R et al, Antimetastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells Int J Cancer (1993) 53: 471-7.
21. Gansbacher B, Zier K, Daniels B et al, Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med (1990) 172: 1217-24
22. Karp SE, Farber A, Salo JC et al, Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J Immunol (1993) 150. 896-908.
23. Gansbacher B, Bannerji R, Daniels B et al, Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res (1990) 50: 7820-5.
24. Connor J, Bannerji R, Saito S et al, Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med (1993) 177: 1127-34.
25. Cavallo F, Di Pierro F, Giovarelli M et al, Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res (1993) 53: 5067-70.
26. Allione A, Consalvo M, Nanni P et al, Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, EL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res (1994) 54: 6022-6.
27. Tsai S-C J, Gansbacher B, Tait L et al, Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. N Natl Cancer Inst (1993) 85: 546-53.
28. Ley V, Langlade-Demoyen P, Kourlisky P, Larsson-Sciard EL, Interleukin 2 dependent activation of tumor-specific cytotoxic T-lymphocytes in vitro. Eur J Immunol (1991) 21: 851-4.
29. Hock H, Dorsch M, Kunzendorf U et al, Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor or interferon gamma. Proc Natl Acad Sci USA (1993) 90: 2774-8.
30. Watanabe Y, Kuribayashi K, Miyatake S et al, Exogenous expression of mouse interferon g cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity and augmented antitumor immunity. Proc Natl Acad Sci USA (1989) 86: 9456-60.
31. Colombo MP, Forni G, Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol Today (1994) 15: 48-51.
32. Ferrantini M, Proietti E, Sandodonato L et al, a1-interferon gene transfer into metastatic friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res (1993) 53: 1107-12.
33. Schmidt W, Schweighoffer T, Herbst E et al, Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA (1995) 92: 4711-14.
34. Rosenthal FM, Cronin K, Bannerji R et al, Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-g cDNAs. Blood (1994) 83: 1289-98.
35. Raes G, Geldhof A, Vanden-Driessche T et al, Immunogenization of a murine T-cell lymphoma via transfection with interferon-gamma. Leukemia (1995) 1: S121-7.
36. Chakravarty PK, Fuji H, Abu-Hadid MM et al, Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression; potential therapeutic implications. Cancer Immunol Immunother (1992) 35: 347-54.
37. Rosenthal FM, Fruh R, Henschler R et al, Cytokine therapy with gene-transfected cells: single injection of irradiated granulocyte-macrophage colony-stimulating factor-transduced cells accelerates hematopoietic recovery after cytotoxic chemotherapy in mice. Blood (1994) 84: 2960-5.
38. Brach MA, Hass R, Sherman ML et al, Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest (1991) 88: 691-5.
39. Ackerstein A, Kedar E, Slavin S, Use of recombinant human IL-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood (1991) 78: 1212-15.
40. Vourka-Karassis U, Karussis D, Ackerstein A, Slavin S, Enhancement of GVL effect with rIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol (1995) 23: 202-8.
41. Toren A, Ackerstein A, Slavin S, Nagler A, Role of IL-2 in human hematological malignancies. Med Oncol (1995) 12: 177-86.
42. Nagler A, Lanier LL, Cwirla S, Phillips JH, Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol (1989) 143: 3183-91.